Skip to Main Content
Boston University
  • Bostonia
  • BU Today
  • The Brink
  • University Publications

    • Bostonia
    • BU Today
    • The Brink
  • School & College Publications

    • The Record
Other Publications
BU Today
  • Sections
News, Opinion, Community

New Malaria Drug Demands New Standards of Care

SPH professor hopes to change the way antimalarial meds are prescribed

July 18, 2007
  • Nicole Laskowski
Twitter Facebook
SPH Professor Davidson Hamer spent three months in Zambian clinics observing malarial diagnostic testing and treatment. Photo by Kalman Zabarsky

The good news: malaria, which kills a million people each year, is effectively treated with a new drug. The bad news: the better treatment is ten times as expensive as the former treatment, and health workers in sub-Saharan Africa who have been accustomed to handing out antimalarial drugs as a precautionary measure must now change their ways — drastically. Enter Davidson Hamer, an associate professor of international health for the School of Public Health’s Center for International Health, whose research is aimed at minimizing the unnecessary use of a treatment that health workers can no longer afford to distribute freely.

In the spring of 2006, Hamer and a group of eight international doctors and researchers spent three months in Zambia, which three years earlier became the first African country to change the national antimalarial treatment policy to the artemisinin-based combination therapy called artemether-lumefantrine. Hamer and the researchers visited health clinics all over the country, asking patients who complained of classic signs of malaria  — headache, fever, chills, and other flu-like symptoms — about the type of treatment they received.

Hamer’s study, which was published in the Journal of American Medical Association in May, found that while 73 percent of health facilities had access to malarial diagnostic equipment, most patients who presented with fever alone were never tested. He also found that two-thirds of those untested patients were given antimalarial medicine. In addition, the clinics often prescribed antimalarial medications to patients who tested negative for the parasite. The problem, according to the World Health Organization, is that resistance to traditional malaria medication is now spreading in all the affected countries, which include nations in East Africa and Southeast Asia.

Hamer’s test results varied with the type of test used for diagnosis. When the test used microscopy, 58.4 percent of patients with a negative diagnosis received antimalarial medication. When clinicians used a rapid antigen-detection diagnostic tests (RDTs), which require blood samples to be mixed with chemicals and tested on a special strip of cellulose, 35.5 percent of patients with a negative diagnosis received treatment. Hamer says he suspects that medical workers may be assuming that a negative blood smear could mean that the parasite is in the body, but hasn’t made its way into the bloodstream yet.

“Ideally,” he says, “you should retest. But this is impractical because people have come a long way to the clinic, so they’ll just treat for malaria. At this point we really don’t know why people are making these choices. That’s something we will hopefully be looking at in future studies.”

In the meantime, Hamer is trying to change the malaria diagnosis and treatment practices of primary health care workers in Zambia and Kenya. One effort involves paying a “small cash bonus” to health care workers who reach certain targets in terms of using the correct drug, dose, and duration of treatment, as documented by a supervisor.

He is also working on a proposal to introduce a text-messaging system in Kenya, a country where more than 85 percent of primary health care workers who treat malaria have mobile phones. With text messaging, he says, messages could be sent several times a day reminding workers of things like proper dosage.

“After the initial training, there aren’t many rounds of retraining, nor are there regular reminders or adequate supervision to reinforce some of the key things primary health care workers need to take away from training,” says Hamer. “By using short text messages, we’re going to try to enhance that.”

Nicole Laskowski can be reached at nicolel@bu.edu.


Explore Related Topics:

  • Drugs
  • Global
  • Share this story

Share

New Malaria Drug Demands New Standards of Care

Share

  • Twitter
  • Facebook
  • Reddit
  • LinkedIn
  • Email
  • Nicole Laskowski

    Nicole Laskowski Profile

Latest from BU Today

  • Things-To-Do

    The Weekender: April 24 to 27

  • Student Clubs

    Afraid of Public Speaking? This Club Can Help

  • Voices & Opinion

    POV: There Are Ways to Make Life Easier for Patients with Alzheimer’s Disease and Their Caregivers

  • Alumni

    The Rise of a Powerhouse BU Department: Economics

  • Innovation

    25 Years of Innovate@BU’s New Venture Competition Showcases Decades of BU Innovation

  • Watch Now

    International Relations vs Political Science: What’s the Difference Between These Majors?

  • University News

    School of Theology Adjusts to New Reality: Ministry Expands Beyond Church

  • Accolades

    BU Honors Best Student Employees and Student Supervisor

  • Watch Now

    Enjoy the Zen on BU’s Campus

  • REVOLUTIONARY WAR QUIZ

    Who Won a BU Swag Bag by Correctly Answering Our Revolutionary War Quiz?

  • Arts & Culture

    Inner Strength Gospel Choir Finds Its Way Under New Director

  • Marathon

    These Seven Terriers Are Running the Boston Marathon to Help Others

  • Business & Law

    Is the United States Heading for an Economic Crisis?

  • Things-to-do

    The Weekender: April 17 to 21

  • Safety

    How to Celebrate Marathon Monday While Staying Safe and Healthy

  • Theatre

    Forget “Barbenheimer.” Try “Desdemilia.”

  • University News

    New BU Initiative Focused on Elevating Classroom Experiences Through Greater Collaboration

  • Fine Arts

    Dozens of Dazzling Projects on View in Annual School of Visual Arts MFA Thesis Exhibitions

  • EVERYTHING GUIDE

    Your Everything Guide to Running in Boston

  • Student Life

    Transfer Students Find Community with Transition to BU Club

Section navigation

  • Sections
  • Must Reads
  • Videos
  • Series
  • Close-ups
  • Archives
  • About + Contact
Get Our Email

Explore Our Publications

Bostonia

Boston University’s Alumni Magazine

BU Today

News, Opinion, Community

The Brink

Pioneering Research from Boston University

  • Twitter
  • Facebook
  • Youtube
  • LinkedIn
  • Instagram
  • Weibo
  • TikTok
© Boston University. All rights reserved. www.bu.edu
© 2025 Trustees of Boston University Privacy Statement Accessibility
Boston University
Notice of Non-Discrimination: Boston University prohibits discrimination and harassment on the basis of race, color, natural or protective hairstyle, religion, sex or gender, age, national origin, ethnicity, shared ancestry and ethnic characteristics, physical or mental disability, sexual orientation, gender identity and/or expression, genetic information, pregnancy or pregnancy-related condition, military service, marital, parental, veteran status, or any other legally protected status in any and all educational programs or activities operated by Boston University. Retaliation is also prohibited. Please refer questions or concerns about Title IX, discrimination based on any other status protected by law or BU policy, or retaliation to Boston University’s Executive Director of Equal Opportunity/Title IX Coordinator, at titleix@bu.edu or (617) 358-1796. Read Boston University’s full Notice of Nondiscrimination.
Search
Boston University Masterplate
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
New Malaria Drug Demands New Standards of Care
0
share this